Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986406 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986406 (Monotherapy Dose Escalation) | EXPERIMENTAL | - |
| Part 1B: BMS-986406 + Nivolumab (Combination Dose Escalation) | EXPERIMENTAL | - |
| Part 1C: BMS-986406 + Nivolumab (Indication-Specific Dose Expansion) | EXPERIMENTAL | - |
| Part 2: BMS-986406 + Nivolumab (Expansion Cohorts) | EXPERIMENTAL | - |
| Part 1D: BMS-986406 + Nivolumab + Carboplatin with Pemetrexed or Paclitaxel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986406 | BIOLOGICAL | Specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
| Carboplatin | DRUG | Specified dose on specified days |
| Pemetrexed | DRUG | Specified dose on specified days |
| Paclitaxel | DRUG | Specified dose on specified days |
Inclusion Criteria: Parts 1A, 1B, 1C: * Histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent malignant tumor. Eligible tumor types are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
BMS-986406 is an investigational monoclonal antibody being studied for the treatment of advanced cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being evaluated as a potential therapy for patients with advanced tumors.
BMS-986406 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced cancer.
BMS-986406 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of advanced cancer, and its safety and effectiveness are still being evaluated in clinical trials.
BMS-986406 has been studied in one clinical trial, identified as NCT05298592, titled "A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors." This Phase 1 trial has been completed and enrolled 77 participants with advanced cancer across the United States, Argentina, Belgium, Japan, South Korea, and Spain.
BMS-986406 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of advanced cancer. The drug has not yet completed the clinical trials and regulatory review process required for approval, and its safety and efficacy are still being evaluated.